Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population

Alessandro Cucchetti, Franco Trevisani, Matteo Cescon, Giorgio Ercolani, Fabio Farinati, Paolo Del Poggio, Gianludovico Rapaccini, Maria Anna Di Nolfo, Luisa Benvegnù, Marco Zoli, Franco Borzio, Edoardo Giovanni Giannini, Eugenio Caturelli, Maria Chiaramonte, Antonio Daniele Pinna

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background & Aims: It was recently shown that semi-annual surveillance for hepatocellular carcinoma (HCC) in cirrhotic patients provides a prognostic advantage over the annual program; however, its cost-effectiveness (CE) in the general cirrhotic population still needs to be defined. Methods: A Markov model was built to compare CE of these two strategies, considering literature results and treatment modalities of 918 cirrhotic patients from the Italian Liver Cancer (ITA.LI.CA) database. Results: Results from the Markov model suggest that, compared to annual surveillance, semi-annual surveillance leads to a gain in quality-adjusted life expectancy, in an unselected cirrhotic population, of 1.35 quality-adjusted life-months (QALMs) over 10 years since surveillance start in compensated patients, and of 0.73 QALMs in decompensated patients. Semi-annual surveillance was more cost-effective in compensated than in decompensated cirrhosis, with an incremental CE ratio (ICER) of 1997 and 3814 €/QALM, respectively. In compensated cirrhosis, semi-annual surveillance was more cost-effective than the annual program when the annual HCC incidence was ≥3.2% and the relative survival gain after cancer diagnosis was ≥20% with respect to the annual program. In decompensated cirrhosis, semi-annual surveillance was cost-effective in patients amenable to liver transplantation. In both groups, CE of semi-annual surveillance improved with the increase of annual incidence and the survival benefit obtainable with HCC treatment. Conclusions: Both surveillance strategies for HCC in cirrhotic patients can be recommended, according to the individual risk profile for HCC occurrence and the expected survival gain obtainable after tumor diagnosis and therapy.

Original languageEnglish
Pages (from-to)1089-1096
Number of pages8
JournalJournal of Hepatology
Volume56
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Liver Neoplasms
Cost-Benefit Analysis
Hepatocellular Carcinoma
Quality of Life
Population
Fibrosis
Costs and Cost Analysis
Survival
Incidence
Life Expectancy
Liver Transplantation
Neoplasms
Therapeutics
Databases

Keywords

  • Cirrhosis
  • Cost-effectiveness
  • Diagnosis
  • Hepatocellular carcinoma
  • Markov model
  • Surveillance

ASJC Scopus subject areas

  • Hepatology

Cite this

Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. / Cucchetti, Alessandro; Trevisani, Franco; Cescon, Matteo; Ercolani, Giorgio; Farinati, Fabio; Poggio, Paolo Del; Rapaccini, Gianludovico; Nolfo, Maria Anna Di; Benvegnù, Luisa; Zoli, Marco; Borzio, Franco; Giannini, Edoardo Giovanni; Caturelli, Eugenio; Chiaramonte, Maria; Pinna, Antonio Daniele.

In: Journal of Hepatology, Vol. 56, No. 5, 05.2012, p. 1089-1096.

Research output: Contribution to journalArticle

Cucchetti, A, Trevisani, F, Cescon, M, Ercolani, G, Farinati, F, Poggio, PD, Rapaccini, G, Nolfo, MAD, Benvegnù, L, Zoli, M, Borzio, F, Giannini, EG, Caturelli, E, Chiaramonte, M & Pinna, AD 2012, 'Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population', Journal of Hepatology, vol. 56, no. 5, pp. 1089-1096. https://doi.org/10.1016/j.jhep.2011.11.022
Cucchetti, Alessandro ; Trevisani, Franco ; Cescon, Matteo ; Ercolani, Giorgio ; Farinati, Fabio ; Poggio, Paolo Del ; Rapaccini, Gianludovico ; Nolfo, Maria Anna Di ; Benvegnù, Luisa ; Zoli, Marco ; Borzio, Franco ; Giannini, Edoardo Giovanni ; Caturelli, Eugenio ; Chiaramonte, Maria ; Pinna, Antonio Daniele. / Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. In: Journal of Hepatology. 2012 ; Vol. 56, No. 5. pp. 1089-1096.
@article{a6df118fac204763a880421a24ab70f4,
title = "Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population",
abstract = "Background & Aims: It was recently shown that semi-annual surveillance for hepatocellular carcinoma (HCC) in cirrhotic patients provides a prognostic advantage over the annual program; however, its cost-effectiveness (CE) in the general cirrhotic population still needs to be defined. Methods: A Markov model was built to compare CE of these two strategies, considering literature results and treatment modalities of 918 cirrhotic patients from the Italian Liver Cancer (ITA.LI.CA) database. Results: Results from the Markov model suggest that, compared to annual surveillance, semi-annual surveillance leads to a gain in quality-adjusted life expectancy, in an unselected cirrhotic population, of 1.35 quality-adjusted life-months (QALMs) over 10 years since surveillance start in compensated patients, and of 0.73 QALMs in decompensated patients. Semi-annual surveillance was more cost-effective in compensated than in decompensated cirrhosis, with an incremental CE ratio (ICER) of 1997 and 3814 €/QALM, respectively. In compensated cirrhosis, semi-annual surveillance was more cost-effective than the annual program when the annual HCC incidence was ≥3.2{\%} and the relative survival gain after cancer diagnosis was ≥20{\%} with respect to the annual program. In decompensated cirrhosis, semi-annual surveillance was cost-effective in patients amenable to liver transplantation. In both groups, CE of semi-annual surveillance improved with the increase of annual incidence and the survival benefit obtainable with HCC treatment. Conclusions: Both surveillance strategies for HCC in cirrhotic patients can be recommended, according to the individual risk profile for HCC occurrence and the expected survival gain obtainable after tumor diagnosis and therapy.",
keywords = "Cirrhosis, Cost-effectiveness, Diagnosis, Hepatocellular carcinoma, Markov model, Surveillance",
author = "Alessandro Cucchetti and Franco Trevisani and Matteo Cescon and Giorgio Ercolani and Fabio Farinati and Poggio, {Paolo Del} and Gianludovico Rapaccini and Nolfo, {Maria Anna Di} and Luisa Benvegn{\`u} and Marco Zoli and Franco Borzio and Giannini, {Edoardo Giovanni} and Eugenio Caturelli and Maria Chiaramonte and Pinna, {Antonio Daniele}",
year = "2012",
month = "5",
doi = "10.1016/j.jhep.2011.11.022",
language = "English",
volume = "56",
pages = "1089--1096",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population

AU - Cucchetti, Alessandro

AU - Trevisani, Franco

AU - Cescon, Matteo

AU - Ercolani, Giorgio

AU - Farinati, Fabio

AU - Poggio, Paolo Del

AU - Rapaccini, Gianludovico

AU - Nolfo, Maria Anna Di

AU - Benvegnù, Luisa

AU - Zoli, Marco

AU - Borzio, Franco

AU - Giannini, Edoardo Giovanni

AU - Caturelli, Eugenio

AU - Chiaramonte, Maria

AU - Pinna, Antonio Daniele

PY - 2012/5

Y1 - 2012/5

N2 - Background & Aims: It was recently shown that semi-annual surveillance for hepatocellular carcinoma (HCC) in cirrhotic patients provides a prognostic advantage over the annual program; however, its cost-effectiveness (CE) in the general cirrhotic population still needs to be defined. Methods: A Markov model was built to compare CE of these two strategies, considering literature results and treatment modalities of 918 cirrhotic patients from the Italian Liver Cancer (ITA.LI.CA) database. Results: Results from the Markov model suggest that, compared to annual surveillance, semi-annual surveillance leads to a gain in quality-adjusted life expectancy, in an unselected cirrhotic population, of 1.35 quality-adjusted life-months (QALMs) over 10 years since surveillance start in compensated patients, and of 0.73 QALMs in decompensated patients. Semi-annual surveillance was more cost-effective in compensated than in decompensated cirrhosis, with an incremental CE ratio (ICER) of 1997 and 3814 €/QALM, respectively. In compensated cirrhosis, semi-annual surveillance was more cost-effective than the annual program when the annual HCC incidence was ≥3.2% and the relative survival gain after cancer diagnosis was ≥20% with respect to the annual program. In decompensated cirrhosis, semi-annual surveillance was cost-effective in patients amenable to liver transplantation. In both groups, CE of semi-annual surveillance improved with the increase of annual incidence and the survival benefit obtainable with HCC treatment. Conclusions: Both surveillance strategies for HCC in cirrhotic patients can be recommended, according to the individual risk profile for HCC occurrence and the expected survival gain obtainable after tumor diagnosis and therapy.

AB - Background & Aims: It was recently shown that semi-annual surveillance for hepatocellular carcinoma (HCC) in cirrhotic patients provides a prognostic advantage over the annual program; however, its cost-effectiveness (CE) in the general cirrhotic population still needs to be defined. Methods: A Markov model was built to compare CE of these two strategies, considering literature results and treatment modalities of 918 cirrhotic patients from the Italian Liver Cancer (ITA.LI.CA) database. Results: Results from the Markov model suggest that, compared to annual surveillance, semi-annual surveillance leads to a gain in quality-adjusted life expectancy, in an unselected cirrhotic population, of 1.35 quality-adjusted life-months (QALMs) over 10 years since surveillance start in compensated patients, and of 0.73 QALMs in decompensated patients. Semi-annual surveillance was more cost-effective in compensated than in decompensated cirrhosis, with an incremental CE ratio (ICER) of 1997 and 3814 €/QALM, respectively. In compensated cirrhosis, semi-annual surveillance was more cost-effective than the annual program when the annual HCC incidence was ≥3.2% and the relative survival gain after cancer diagnosis was ≥20% with respect to the annual program. In decompensated cirrhosis, semi-annual surveillance was cost-effective in patients amenable to liver transplantation. In both groups, CE of semi-annual surveillance improved with the increase of annual incidence and the survival benefit obtainable with HCC treatment. Conclusions: Both surveillance strategies for HCC in cirrhotic patients can be recommended, according to the individual risk profile for HCC occurrence and the expected survival gain obtainable after tumor diagnosis and therapy.

KW - Cirrhosis

KW - Cost-effectiveness

KW - Diagnosis

KW - Hepatocellular carcinoma

KW - Markov model

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=84859702722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859702722&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2011.11.022

DO - 10.1016/j.jhep.2011.11.022

M3 - Article

VL - 56

SP - 1089

EP - 1096

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 5

ER -